Sentences with phrase «of imatinib»

[44] Two other phase II clinical trials evaluated the efficacy of imatinib in patients with melanoma — including mucosal melanomas — harboring KIT mutations and / or amplifications, with a subset of cases involving mucosal primaries, and both found a disease control rate of approximately 50 %.

Phase II, open - label, single - arm trial of imatinib mesylate in patients with metastatic melanoma harboring c - Kit mutation or amplification.

Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia.

Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia

The researchers have shown that the binding of imatinib unexpectedly shifts this equilibrium to the open state.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

In its second line of argument, Teva stated that the incorrect interpretation of Article 8 has the effect of unjustifiably extending orphan exclusivity of imatinib beyond the ten - year period and consequently denying it the opportunity to submit application and obtain approval for a generic equivalent.

In contrast, when the animals were treated with a combination of imatinib and PGE1, those numbers were greatly reduced, and mice did not develop leukemia.

«To our knowledge, this is the first randomized trial regarding the discontinuation of imatinib in first chronic phase CML patients who have achieved a durable and stable molecular response,» the authors wrote.

However, after months or years of imatinib the cancer may develop a resistance so the drug loses its effectiveness.

Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M Dynamic modeling of imatinib - treated chronic myeloid leukemia: functional insights and clinical implications.

The use of imatinib has dramatically improved treatment results for adults with c - KIT (CD117 positive) GIST.

After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML, which led to FDA approval of the drug in record time.

Dr. Druker's role in the development of imatinib and its application in the clinic has resulted in numerous awards for Dr. Druker, including the AACR - Richard and Hinda Rosenthal Award, the Warren Alpert Prize from Harvard Medical School, the 2009 Lasker - DeBakey Award for Clinical Medical Research, the Japan Prize in Healthcare and Medical Technology and the Albany Medical Center Prize in Medicine and Biomedical Research.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo - controlled, phase 3 trial.

In November 2007 another Novartis drug, Tasigna ® (nilotinib), was submitted for marketing authorization for CML, but since it was found to be structurally similar to imatinib by the EMA, Novartis was obligated to obtain consent from the first marketing authorization holder under Article 8 (3)(a) of the Orphan Drugs Regulation due to the existing orphan exclusivity of imatinib.

Our group treated 11 patients with advanced mucosal melanoma harboring KIT alterations as part of our completed phase II trial of imatinib.

Future studies will test and compare the efficacy of imatinib and allosteric compounds in mouse models of breast cancer.